Pathogenesis of Human Systemic Lupus Erythematosus: A Cellular Perspective
Vaishali R. Moulton,Abel Suárez-Fueyo,Esra Meidan,Esra Meidan,Hao Li,Masayuki Mizui,George C. Tsokos +6 more
Reads0
Chats0
TLDR
Novel observations have provided an improved understanding of the contribution of tissue-specific factors and associated damage, T and B lymphocytes, as well as innate immune cell subsets and their corresponding abnormalities.About:
This article is published in Trends in Molecular Medicine.The article was published on 2017-07-01 and is currently open access. It has received 288 citations till now. The article focuses on the topics: Immune dysregulation & Autoimmunity.read more
Citations
More filters
Journal ArticleDOI
Sex Hormones in Acquired Immunity and Autoimmune Disease.
TL;DR: The role of sex hormones particularly estrogen, in the adaptive immune response, in health, and autoimmune disease with an emphasis on systemic lupus erythematosus is focused on.
Journal ArticleDOI
Autoimmunity and organ damage in systemic lupus erythematosus
TL;DR: Tsokos reviews how the genetic, epigenetic and microbial environments influence innate and adaptive immune cells to drive immunopathology and organ damage in systemic lupus erythematosus.
Journal ArticleDOI
Th17 Cells and the IL-23/IL-17 Axis in the Pathogenesis of Periodontitis and Immune-Mediated Inflammatory Diseases
Kübra Bunte,Thomas Beikler +1 more
TL;DR: A review of the current knowledge about the differentiation of Th17 cells and the role of the IL-17/IL-23 axis in the pathogenesis of IMIDs aims to review the association of these IMIDs with periodontitis and briefly discusses the therapeutic potential of agents that modulate the IL
Journal ArticleDOI
Regulatory T cells in the treatment of disease
TL;DR: The current progress in modulating Treg cells in autoimmune disorders, transplantation and cancer is described to promote antitumour immunity and regression.
Journal ArticleDOI
Aberrant T Cell Signaling and Subsets in Systemic Lupus Erythematosus.
TL;DR: A better understanding of the molecular defects including signaling events and gene regulation underlying the dysfunctional T cells in SLE is necessary to pave the path for better management, therapy, and perhaps prevention of this complex disease.
References
More filters
Journal ArticleDOI
STAT4 associates with systemic lupus erythematosus through two independent effects that correlate with gene expression and act additively with IRF5 to increase risk
Anna-Karin Abelson,Angelica M. Delgado-Vega,Sergey V. Kozyrev,Elena Sánchez,Rafael Velázquez-Cruz,Niclas Eriksson,Jérôme Wojcik,Prasad M V Linga Reddy,Guadalupe Lima,Sandra D'Alfonso,Sergio Migliaresi,Vicente Baca,Lorena Orozco,Torsten Witte,Norberto Ortego-Centeno,Hadi Abderrahim,Bernardo A. Pons-Estel,Carmen Gutiérrez,Ana Suárez,María Francisca González-Escribano,Javier Martín,Marta E. Alarcón-Riquelme,Marta E. Alarcón-Riquelme +22 more
TL;DR: The data confirm STAT4 as a susceptibility gene for SLE and suggest the presence of at least two functional variants affecting levels of STAT4, and indicate that the genes STAT4 and IRF5 act additively to increase the risk of SLE.
Journal ArticleDOI
T cell signaling abnormalities contribute to aberrant immune cell function and autoimmunity
TL;DR: A better understanding of signaling and gene regulation defects in SLE T cells will lead to the identification of specific novel molecular targets and predictive biomarkers for therapy.
Journal ArticleDOI
Phosphorylated ERM Is Responsible for Increased T Cell Polarization, Adhesion, and Migration in Patients with Systemic Lupus Erythematosus
Yansong Li,Tatsuhiro Harada,Yuang-Taung Juang,Yuang-Taung Juang,Vasileios C. Kyttaris,Vasileios C. Kyttaris,Vasileios C. Kyttaris,Ying Wang,Michael Zidanic,Kenneth S. K. Tung,George C. Tsokos,George C. Tsokos +11 more
TL;DR: Increased ERM phosphorylation represents a key molecular abnormality that guides T cell adhesion and migration in SLE patients, and it is proved that pERM and CD44 are highly expressed in T cells infiltrating in the kidneys of patients with lupus nephritis.
Journal ArticleDOI
Cytokines as therapeutic targets in SLE
Lars Rönnblom,Keith B. Elkon +1 more
TL;DR: The rationale for anticytokine therapies in SLE is discussed and review agents currently in use, and those being developed and tested experimentally, as well as suggestions for the future of treatment for SLE, including new therapeutic strategies.
Journal ArticleDOI
Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial
TL;DR: Lupuzor/200 µg given three times at 4-week intervals during 12 weeks in addition to standard of care (SOC) is efficacious and generally well tolerated.
Related Papers (5)
Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.
Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus.
Michelle Petri,Ana Maria Orbai,Graciela S. Alarcón,Caroline Gordon,Joan T. Merrill,Paul R. Fortin,Ian N. Bruce,David A. Isenberg,Daniel J. Wallace,Ola Nived,Gunnar Sturfelt,Rosalind Ramsey-Goldman,Sang Cheol Bae,John G. Hanly,Jorge Sanchez-Guerrero,Ann E. Clarke,Cynthia Aranow,Susan Manzi,Murray B. Urowitz,Dafna D. Gladman,Kenneth C. Kalunian,Melissa Costner,Victoria P. Werth,Asad Zoma,Sasha Bernatsky,Guillermo Ruiz-Irastorza,Munther A. Khamashta,Søren Jacobsen,Jill P. Buyon,Peter J. Maddison,Mary Anne Dooley,Ronald F van Vollenhoven,Ellen M. Ginzler,Thomas Stoll,Christine A. Peschken,Joseph L. Jorizzo,Jeffrey P. Callen,S. Sam Lim,Barri J. Fessler,Murat Inanc,Diane L. Kamen,Anisur Rahman,Kristjan Steinsson,Andrew G. Franks,Lisa Sigler,Suhail Hameed,Hong Fang,Ngoc Minh Pham,Robin L. Brey,Michael H. Weisman,Gerald McGwin,Laurence S. Magder +51 more